Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of CFTR modulators in special populations, part 2: Severe lung disease.

Pediatric pulmonology - 1 Dec 2023

Elijah Joseph, Fitzgerald Linda J, Phan Hanna

Abstract excerpt

Safety and efficacy data surrounding cystic fibrosis transmembrane regulator (CFTR) modulator administration for people with CF (pwCF) and severe lung disease elect has remained unclear as a result of exclusion from key trials. A scoping review of English language articles from the period of 1 January 2012, to 31 July 2023 was conducted utilizing PubMed and EmBase databases with the following terms: "severe lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aminophenols
Share to Anti-Bacterial Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Quality of Life

Source

Identifiers

PMID: 37728222
DOI: 10.1002/ppul.26698

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of CFTR modulators in special populations, part 2: Severe lung disease.PMID 37728222Read ↗

Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation.Semantic proximity Read ↗

Use of CFTR modulators in special populations, part 3: Solid organ transplant.Semantic proximity Read ↗

Use of CFTR modulators in special populations, part 1: Pregnancy and lactation.Semantic proximity Read ↗

The New and Advanced Cystic fibrosis transmembrane conductance regulators Modulators in Children with Cystic Fibrosis: A Narrative Review on Long-Term Outcomes, Recent Advances, and Comparative Insights.Semantic proximity Read ↗

Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.Semantic proximity Read ↗

Review of CFTR modulators 2020.Semantic proximity Read ↗

CFTR Modulators: Current Status and Evolving Knowledge.Semantic proximity Read ↗

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in FranceSemantic proximity Read ↗

Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease.Semantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational StudySemantic proximity Read ↗

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity Read ↗

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.